PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.

Metastatic castration-resistant prostate cancer Overall survival PSMA PET/CT Prostate-specific membrane antigen Treatment response evaluation mCRPC

Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
02 Oct 2024
Historique:
received: 09 07 2024
revised: 10 09 2024
accepted: 30 09 2024
medline: 24 10 2024
pubmed: 24 10 2024
entrez: 23 10 2024
Statut: aheadofprint

Résumé

In metastatic castration-resistant prostate cancer (mCRPC), using serum prostate-specific antigen (PSA) levels to evaluate treatment response is not always accurate. This study aimed to assess the efficacy of PSMA PET/CT at specific time points for evaluating treatment response and predicting survival in mCRPC patients, compared to PSA. Sixty mCRPC patients underwent [ PSMA PET/CT and PSA response were discordant in 47 % of patients, and PSMA PET/CT response was worse in 89 % of these cases. Overall response on PSMA PET/CT independently predicted overall survival (progression versus non-progression: HR = 4.05, p < 0.001), outperforming PSA response (progression versus non-progression: HR = 2.53, p = 0.010) and other PSMA PET/CT parameters. Among patients with a PSA decline of > 50 %, 31 % showed progressive disease on PSMA PET/CT, correlating with higher mortality risk (progression versus non-progression: HR = 4.38, p = 0.008). No flare in PSMA uptake was observed in this cohort. PSMA PET/CT for assessing treatment response at predefined time points was superior to PSA-based response for predicting overall survival in mCRPC patients treated with androgen receptor-targeted agents and chemotherapy. PSMA PET/CT showed the ability to detect disease progression earlier than PSA levels, which can affect treatment decisions and has the potential to improve patient outcomes. We recommend further research to validate these findings in larger patient cohorts, to extend the number of treatments, and to evaluate cost-effectiveness and impact on patient outcomes.

Sections du résumé

BACKGROUND BACKGROUND
In metastatic castration-resistant prostate cancer (mCRPC), using serum prostate-specific antigen (PSA) levels to evaluate treatment response is not always accurate. This study aimed to assess the efficacy of PSMA PET/CT at specific time points for evaluating treatment response and predicting survival in mCRPC patients, compared to PSA.
METHODS METHODS
Sixty mCRPC patients underwent [
RESULTS RESULTS
PSMA PET/CT and PSA response were discordant in 47 % of patients, and PSMA PET/CT response was worse in 89 % of these cases. Overall response on PSMA PET/CT independently predicted overall survival (progression versus non-progression: HR = 4.05, p < 0.001), outperforming PSA response (progression versus non-progression: HR = 2.53, p = 0.010) and other PSMA PET/CT parameters. Among patients with a PSA decline of > 50 %, 31 % showed progressive disease on PSMA PET/CT, correlating with higher mortality risk (progression versus non-progression: HR = 4.38, p = 0.008). No flare in PSMA uptake was observed in this cohort.
CONCLUSIONS CONCLUSIONS
PSMA PET/CT for assessing treatment response at predefined time points was superior to PSA-based response for predicting overall survival in mCRPC patients treated with androgen receptor-targeted agents and chemotherapy. PSMA PET/CT showed the ability to detect disease progression earlier than PSA levels, which can affect treatment decisions and has the potential to improve patient outcomes. We recommend further research to validate these findings in larger patient cohorts, to extend the number of treatments, and to evaluate cost-effectiveness and impact on patient outcomes.

Identifiants

pubmed: 39442347
pii: S0720-048X(24)00490-X
doi: 10.1016/j.ejrad.2024.111774
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111774

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

F Kleiburg (F)

Biomedical Photonic Imaging Group, University of Twente, Enschede, the Netherlands; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: F.Kleiburg@lumc.nl.

L F de Geus-Oei (LF)

Biomedical Photonic Imaging Group, University of Twente, Enschede, the Netherlands; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Centre, Leiden, the Netherlands; Department of Radiation Science & Technology, Delft University of Technology, Delft, the Netherlands.

S A C Luelmo (SAC)

Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.

R Spijkerman (R)

Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Centre, Leiden, the Netherlands.

J J Goeman (JJ)

Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands.

F A J Toonen (FAJ)

Department of Oncology, Alrijne Hospital, Leiderdorp, the Netherlands.

F Smit (F)

Department of Nuclear Medicine, Alrijne Hospital, Leiderdorp, the Netherlands.

T van der Hulle (T)

Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.

L Heijmen (L)

Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Centre, Leiden, the Netherlands.

Classifications MeSH